A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral AKT Inhibitor GSK2110183 in Subjects With Any Hematologic Malignancy.

Trial Profile

A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral AKT Inhibitor GSK2110183 in Subjects With Any Hematologic Malignancy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Jul 2014

At a glance

  • Drugs Afuresertib (Primary)
  • Indications Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 03 Apr 2012 Actual patient number 73 added as reported by ClinicalTrials.gov.
    • 03 Apr 2012 Additional trial location (South Korea) identified as reported by ClinicalTrials.gov.
    • 03 Apr 2012 Actual end date Mar 2012 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top